{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T23:28:18Z","timestamp":1748993298290},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,5,1]]},"DOI":"10.1093\/ndt\/15.5.684","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:47:51Z","timestamp":1027723671000},"page":"684-688","source":"Crossref","is-referenced-by-count":28,"title":["Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis"],"prefix":"10.1093","volume":"15","author":[{"given":"Gilles","family":"Hufnagel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Vrtovsnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Queffeulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niloufar","family":"Kossari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Mignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2000,5]]},"reference":[{"key":"key\n\t\t\t\t20180109102312_R1","unstructured":"Lacour B, Massy ZA, Jungers P, Dr\u00fceke T. Anomalies du m\u00e9tabolisme des lipoprot\u00e9ines dans l'insuffisance r\u00e9nale chronique. N\u00e9phrologie1993; 14: 75\u201390"},{"key":"key\n\t\t\t\t20180109102312_R2","doi-asserted-by":"crossref","unstructured":"Attman PO, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int1991; 57: 401\u2013410","DOI":"10.1159\/000186303"},{"key":"key\n\t\t\t\t20180109102312_R3","doi-asserted-by":"crossref","unstructured":"Atkins RC, Wood C. Hyperlipidaemia in CAPD. Perit Dial Int1992; 13 [Suppl 2]: S415\u2013417","DOI":"10.1177\/089686089301302S104"},{"key":"key\n\t\t\t\t20180109102312_R4","unstructured":"Cocchi R, Viglino G, Cancarini G et al. Prevalence of hyperlipidaemia in a cohort of CAPD patients. Miner Electrolyte Metab1996; 66: 22\u201325"},{"key":"key\n\t\t\t\t20180109102312_R5","doi-asserted-by":"crossref","unstructured":"Appel GB. Lipids abnormalities in renal disease. Kidney Int1991; 39: 169\u2013183","DOI":"10.1038\/ki.1991.22"},{"key":"key\n\t\t\t\t20180109102312_R6","doi-asserted-by":"crossref","unstructured":"Kasiske BL. Hyperlipidaemia in patients with chronic renal disease. Am J Kidney Dis1998; 32 [Suppl 3]: 142\u2013156","DOI":"10.1053\/ajkd.1998.v32.pm9820472"},{"key":"key\n\t\t\t\t20180109102312_R7","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis1996; 27: 1\u201325","DOI":"10.1016\/S0272-6386(96)90026-8"},{"key":"key\n\t\t\t\t20180109102312_R8","doi-asserted-by":"crossref","unstructured":"Assman G, Schulte H. Relation of high density lipoprotein, cholesterol and triglycerides to incidence of atherosclerosis coronary artery disease. The PROCAM experience. Am J Cardiol1992; 70: 733\u2013737","DOI":"10.1016\/0002-9149(92)90550-I"},{"key":"key\n\t\t\t\t20180109102312_R9","doi-asserted-by":"crossref","unstructured":"Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high\u2010density lipoprotein cholesterol level: a meta\u2010analysis of population\u2010based prospective studies. J. Cardiovasc Risk1996; 3: 213\u2013229","DOI":"10.1097\/00043798-199604000-00014"},{"key":"key\n\t\t\t\t20180109102312_R10","doi-asserted-by":"crossref","unstructured":"Jeppesen J, Hein HO, Suadicani P et al. Triglyceride concentration and ischemic heart disease. An eight\u2010year follow\u2010up in the Copenhagen Male Study. Circulation1998; 97: 1029\u20131036","DOI":"10.1161\/01.CIR.97.11.1029"},{"key":"key\n\t\t\t\t20180109102312_R11","doi-asserted-by":"crossref","unstructured":"Appel B, Jacobs C, Markell MS. How should the lipid abnormalities of dialysis patients be treated? Semin Dial1995; 8: 15\u201321","DOI":"10.1111\/j.1525-139X.1995.tb00319.x"},{"key":"key\n\t\t\t\t20180109102312_R12","doi-asserted-by":"crossref","unstructured":"Mattys E, Schurgers M, Lamberigts G et al. Effects of simvastatin treatment on the dyslipoproteinaemia in CAPD patients. Atherosclerosis1991; 86: 183\u2013192","DOI":"10.1016\/0021-9150(91)90214-N"},{"key":"key\n\t\t\t\t20180109102312_R13","doi-asserted-by":"crossref","unstructured":"Li PK, Mak TW, Chiu K et al. Effect of lovastatin on serum lipid profile in the treatment of dyslipoproteinaemia in uraemic patients on continuous ambulatory peritoneal dialysis. Aust NZ J Med1993; 23: 252\u2013257","DOI":"10.1111\/j.1445-5994.1993.tb01727.x"},{"key":"key\n\t\t\t\t20180109102312_R14","doi-asserted-by":"crossref","unstructured":"Nawrocki JW, Weiss SR, Davidson MH et al. Reduction in LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG\u2010CoA reductase inhibitor. Arterioscler Thromb Vasc Biol1995; 15: 678\u2013682","DOI":"10.1161\/01.ATV.15.5.678"},{"key":"key\n\t\t\t\t20180109102312_R15","doi-asserted-by":"crossref","unstructured":"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol1998; 81: 582\u2013587","DOI":"10.1016\/S0002-9149(97)00965-X"},{"key":"key\n\t\t\t\t20180109102312_R16","doi-asserted-by":"crossref","unstructured":"Bakker\u2010Arkema RG, Davidson MH, Goldstein RJ et al. Efficacy and safety of a new HMG\u2010CoA reductase inhibitor, Atorvastatin, in patients with hypertriglyceridemia. JAMA1996; 275: 128\u2013133","DOI":"10.1001\/jama.275.2.128"},{"key":"key\n\t\t\t\t20180109102312_R17","unstructured":"Treatment of high blood cholesterol in adults. Recommandations of the French Association Nationale de l'Evaluation M\u00e9dicale. In Hypolipid\u00e9miants. Concours M\u00e9d1996; [Suppl 41]: 58\u201372"},{"key":"key\n\t\t\t\t20180109102312_R18","unstructured":"Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommandations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis1992; 3: 113\u2013156"},{"key":"key\n\t\t\t\t20180109102312_R19","doi-asserted-by":"crossref","unstructured":"Summary of the Second Report of the National Cholesterol Education Program (NCPE) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel II). JAMA1993; 269: 3015\u20133023","DOI":"10.1001\/jama.269.23.3015"},{"key":"key\n\t\t\t\t20180109102312_R20","unstructured":"Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group, WOSCOPS. Prevention of coronary heart disease in men with hypercholesterolaemia. N Engl J Med1995; 333, 20: 1301\u20131307"},{"key":"key\n\t\t\t\t20180109102312_R21","doi-asserted-by":"crossref","unstructured":"Stern R, Yang BB, Horton M et al. Renal dysfunction does not alter the pharmacokinetics of LDL\u2010cholesterol reduction of atorvastatin. J Clin Pharmacol1997; 37: 816\u2013819","DOI":"10.1002\/j.1552-4604.1997.tb05629.x"},{"key":"key\n\t\t\t\t20180109102312_R22","doi-asserted-by":"crossref","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344: 1383\u20131389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"key\n\t\t\t\t20180109102312_R23","doi-asserted-by":"crossref","unstructured":"Sacks, FM Pfeffer, MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med1996; 335, 14: 1001\u20131009","DOI":"10.1056\/NEJM199610033351401"},{"key":"key\n\t\t\t\t20180109102312_R24","doi-asserted-by":"crossref","unstructured":"Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and IDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation1992; 85: 37\u201345","DOI":"10.1161\/01.CIR.85.1.37"},{"key":"key\n\t\t\t\t20180109102312_R25","doi-asserted-by":"crossref","unstructured":"Gotto AM. The forgotten risk factor. Circulation1998; 97: 1027\u20131028","DOI":"10.1161\/01.CIR.97.11.1027"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/15\/5\/684\/23367676\/150684.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T09:11:32Z","timestamp":1583313092000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/15\/5\/684\/1849962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5,1]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2000,5]]},"published-print":{"date-parts":[[2000,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/15.5.684","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2000,5]]},"published":{"date-parts":[[2000,5,1]]}}}